Sellas Life Sciences Group Inc SLS

$11.54 +0.19 (1.67%)

Valuation

Market cap
2,330,457,000
Revenue TTM
$0
Net income TTM
$-26,860,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
3,279,100
Avg volume
6,584,616
Day's range
$11.08 – $11.59
Shares out
201,946,000
Stochastic %K
61%
Beta
2.56
Analysts
Strong Sell
Price target
$32.50

Price

Company profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It h...

Show more

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
646 200 5278
Website
https://sellaslifesciences.com
Address
7 Times Square, Suite 2503, New York, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Oct 25, 6:31 AM
$SLS 21.4% Front Line Oral Az / 8.7% Oral Az +VEN alive at 3 years. -- Only a rare handful of outliers - in the SLS Regal P3 CONTROL ARM, Post CR1 Relapsed/ Refractory / post Salvage, Second Remission transplant Ineligible Aml Patients remain ALIVE --- Even Assuming the IMPOSSIBLE - same 21% - that would be 13 Patients from the SLS Control ARM --who remain - again assuming the impossible - reality is its likely less than half ... due to greater infirmity and Developed Aza Ven Resistance . ... but again - assuming an Impossible 13 patients from control, there are AT LEAST 48 TOTAL REMAINING ... 35 GPS ...
0 replies
Major_Bagholder Oct 25, 6:31 AM
$SLS $50B is not realistic. It’s fantasy. $15B ~ $20B is possible with HR < .4.
1 replies
BioTechBling Oct 25, 6:19 AM
$SLS Let’s get something straigt! $£$ is capable of licensing 2 TRANSFORMATIVE FIRST IN CLASS assets (GPS & SLS009) & bringing them to expected FDA approval soon… $£$ with brilliant leaders who manage to achieve what all other BP with superior resources cannot… these $£$ leaders now on the cusp of victory are just a bunch of dummies too dumb to preemptively reserve premium ASH booth located right in front of the poster entrance! Yeah right… fyi 2026 ASH REGAL LBA poster is the literally most important PLENARY & thus poster #1 (SLS009 likely in top #10) & right next to $£$ booth! $£$ are guided by knowledgeable consultants like IQVIA… however $£$ LEADERS make all decisions until they are officially bought out as suggesting otherwise put both $£$ & acquiring BP in legal perils! Let’s at least wait until after BO before smoking the pipe!
0 replies
55X_ROI_Q1_2026 Oct 25, 5:57 AM
$SLS blocked this fake ling, short tool. lying pos. Phase 3 results are Imminent.
0 replies
quezoitm Oct 25, 5:13 AM
$SLS $MRNA
1 replies
quezoitm Oct 25, 5:12 AM
$SLS
0 replies
quezoitm Oct 25, 5:11 AM
$SLS The patience is hard. The conviction is easy. Holding til BO.
1 replies
OnTheBalance Oct 25, 4:52 AM
$SLS And NO … to more dumb stuff. 600 sq ft ASH 2026 Booth was NOT booked a year ago. Sellas may have booked a 100 or 200 sq foot booth, or maybe not. But current suitors have booths in the 4000 to 9600 sq ft range. IQVIA is the designated agency. They took care of the assets. 600 sq ft for now is fine. They took care of it. Sellas name is temporary. The caretaker.
2 replies